Erratum: Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin a in healthy subjects (Journal of Clinical Endocrinology and Metabolism (2012) 97:9 (E1731-E1735) DOI: 10.1210/jc.2012-1548);Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 317-

  Mosli, Hala H ^a,e   Dennis, Alan ^b   Kocha, Walter ^c   Asher, Linda J ^a   Van Uum, Stan H M ^a,d  

^a WESTERN UNIVERSITY   (Canada)

^b London Laboratory Services Group   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANALYTICAL EQUIPMENT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD SAMPLING; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 84866145912     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.20144157     Document Type: Erratum

References (15)

1. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW 1998 Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 28:431-440 (Pubitemid 28326407)
2. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D 2008 Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 14:5377-5384
3. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P 2007 Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967-1973 (Pubitemid 46972778)
4. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK 1996 Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39:649-653 (Pubitemid 26426463)
5. Glinicki P, Jeske W 2010 Chromogranin A (CgA)-the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood. Endokrynol Pol 61:384-387
6. Kuipers EJ 2006 Proton pump inhibitors and gastric neoplasia. Gut 55:1217-1221 (Pubitemid 44277346)
7. Cramer T, Jüttner S, Plath T, Mergler S, Seufferlein T, Wang TC, Merchant J, Höcker M 2008 Gastrin transactivates the chromogranin A gene through MEK-1/ERK- and PKC-dependent phosphorylation of Sp1 and CREB. Cell Signal 20:60-72 (Pubitemid 350138370)
8. Kim BW, Lee BI, Kim HK, Cho YS, Chae HS, Lee HK, Kim HJ, Han SW 2009 Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin. Korean J Gastroenterol 53:84-89
9. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F 2004 Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 150:299-303 (Pubitemid 38443779)
10. Pregun I, Herszényi L, Juhász M, Miheller P, Hritz I, Patócs A, Rácz K, Tulassay Z 2011 Effect of proton-pump inhibitor therapy on serum chromogranin A level. Digestion 84:22-28
11. Sanduleanu S, De Bruïne A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, Lundqvist G, Stockbrügger RW 2001 Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 31:802-811 (Pubitemid 34203475)
12. Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d'Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M, Baudin E 2011 Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 26:94-101
13. Korse CM, Muller M, Taal BG 2011 Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 105:1173-1175
14. Fossmark R, Johnsen G, Johanessen E, Waldum HL 2005 Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 21:149-154 (Pubitemid 40222967)
15. Jianu CS, Lange OJ, Viset T, Qvigstad G, Martinsen TC, Fougner R, Kleveland PM, Fossmark R, Hauso Ø, Waldum HL 2012 Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47:64-67